High Sensitivity and Specificity
Compared to conventional tests, immunoassays have been proven to provide highly accurate results even with very small samples. Immunoassays are considered to have a detection limit of 1pg/ml. This can be attributed to the fact that immunoassays are based entirely on immunologic reactions. Immunologic reactions are highly specific as they can take place only in the presence of proper immunologic agents. Immunoassays have a range of applications in pharmaceutical analysis such as diagnosis of disease, therapeutic drug monitoring, clinical pharmacokinetics and bioequivalence in drug discovery and pharmaceutical industries.
Additionally, cost effectives and rapid analysis by the immunoassays and growth in the biotechnology and pharmaceutical sectors are also driving the growth of the Global Immunoassays Market.
Limitations Associated with Immunoassay
Immunoassays have shown high sensitivity and specificity. While this have advantages, there have been many limitations associated with the procedure. The limit of detection (LOD) for most of the immunoassays is limited primarily by the signal-to-noise ratio provided by the instrument that is used to detect antibody-antigen binding or by non-specific binding (NSB). Immunoassays are very complex to develop and manufacture and employs complex biomolecules such as antibodies, antigens and enzymes for the detection of the target molecules. Additionally, complex assay procedures are also acting as a restraint for the global immunoassays market.
North America to Dominate the Market
The market has been segmented by technology into enzyme immunoassay, fluorescence immunoassay, chemiluminescence immunoassay, radioimmunoassay, nephelometric immunoassay, and others. Based on therapeutic areas, it has been segmented into cardiology, thyroid, autoimmune disease, oncology, infectious disease, hematology, allergy, and others. By end user, the market is segmented into hospital, centralized laboratory, academic institution, pharma & biotech firm, contract research organization, and others. The market is segmented on the basis of geography into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The regions have been further divided into major constituent countries.
North America dominates the Global Immunoassays Market which is mainly driven by increasing incidence of chronic disease and use of immunoassays in oncology.
Key Developments in the Market
- September 2017: Meridian Life science Inc. launches TRUBlock Ultra which is an active immunoassay interference blocker created by HAMA, rheumatoid factor (RH) and heterophillic antibodies (HA).
- June 2017: Qiagen developed QFT-Plus which detects latent tuberculosis infection got FDA approval.
REASONS TO PURCHASE THIS REPORT
- Current and future Immunoassays Market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The treatment type that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares and strategies employed by the major market players.
- 3 months analyst support along with the Market Estimate sheet in excel.
This report can be customized to meet your requirements. Please contact us for more information.
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTERS FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 HIGH SENSITIVITY AND SPECIFICITY
6.1.2 COST EFFECTIVENESS
6.1.3 RAPID ANALYSIS BY THE IMMUNOASSAYS
6.1.4 GROWTH IN THE BIOTECHNOLOGY AND PHARMACEUTICAL SECTORS
6.2 MARKET RESTRAINTS
6.2.1 COMPLICATED REGULATORY REQUIREMENTS
6.2.2 COMPLEX ASSAY PROCEDURES
6.2.3 LIMITATIONS ASSOCIATED WITH IMMUNOASSAY
6.4 KEY CHALLENGES
7. Market Segmentation
7.1 BY TECHNOLOGY
7.1.1 ENZYME IMMUNOASSAY
7.1.2 FLUORESCENCE IMMUNOASSAY
7.1.3 CHEMILUMINESCENCE IMMUNOASSAY
7.1.5 NEPHELOMETRIC IMMUNOASSAY
7.2 BY THERAPEUTIC AREA
7.2.3 AUTOIMMUNE DISEASE
7.2.5 INFECTIOUS DISEASE
7.3 BY END USER
7.3.2 CENTRALIZED LABORATORY
7.3.3 ACADEMIC INSTITUTION
7.3.4 PHARMA & BIOTECH FIRM
7.3.5 CONTRACT RESEARCH ORGANIZATION
7.4 SEGEMENTATION BY GEOGRAPHY
7.4.1 NORTH AMERICA
18.104.22.168 UNITED STATES
22.214.171.124 UNITED KINGDOM
126.96.36.199 REST OF EUROPE
188.8.131.52 AUSTRALIA & NEW ZEALAND
184.108.40.206 SOUTH KOREA
220.127.116.11 REST OF ASIA-PACIFIC
7.4.4 MIDDLE EAST AND AFRICA
18.104.22.168 SOUTH AFRICA
22.214.171.124 REST OF MIDDLE EAST AND AFRICA
7.4.5 SOUTH AMERICA
126.96.36.199 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. COMPANY PROFILES
9.1 ABBOTT LABORATORIES INC
9.2 BECTON DICKINSON AND COMPANY
9.3 DANAHER CORPORATION
9.4 EDP BIOTECH CORPORATION
9.6 LUMINEX CORPORATION
9.7 MERIDIAN LIFE SCIENCE INC
10. FUTURE OUTLOOK OF THE MARKET